Vera's Trutakna Hits All Endpoints in Final Phase 3 IgA Nephropathy Trial
- Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the Phase 3 ORIGIN 3 trial in adults with primary IgA nephropathy at risk of disease progression.
- Over 52 weeks, TRUTAKNA stabilized kidney function (eGFR), while patients on placebo continued to decline.
- Through 104 weeks, the drug substantially reduced composite kidney disease progression events, including dialysis, transplant, and death, compared with placebo.
- Secondary measures also improved, including proteinuria, galactose-deficient IgA1, and hematuria, with a safety profile comparable to placebo.
- TRUTAKNA already holds accelerated FDA approval for IgA nephropathy, and Vera plans to file a supplemental BLA in the fourth quarter of 2026 seeking full approval, alongside early positive commercial uptake since launch.
Confirmatory data this clean removes the single biggest overhang on TRUTAKNA's commercial story: accelerated approvals routinely get pulled or delayed when post-marketing trials disappoint, and Vera now walks into its Q4 sBLA filing with full-approval leverage rather than hope. That matters in a field crowding fast — Travere's Filspari, Calliditas/Otsuka's Tarpeyo, Novartis's Fabhalta, and Otsuka's sibeprenlimab are all fighting for the same nephrologists. Atacicept's dual APRIL/BAFF mechanism gives Vera a real differentiation story on upstream disease modification, not just symptom control, which should support pricing and payer positioning as uptake scales. For a company Vera's size, a de-risked full approval also reshapes M&A calculus — this is now a cleaner acquisition target for a larger nephrology or immunology player looking to buy share rather than build it.
Vera kidney drug Trutakna shows strong final results in Phase 3 trial ↗